The irreversibly binding, second-generation inhibitor afatinib received initial U.S. FDA approval and marketing authorization in the EU in 2013 as first-line treatment for patients with metastatic NSCLC with EGFR mutations (Del19 and L858R) [76,77]. Here, EGFR is linked to non-small cell lung carcinoma.